← SynDRA
OSIMERTINIB
SynDRA canonical compound SYN0038115 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx/OTC |
|---|
| Primary target(s) | EGFR |
|---|
| Mechanism of action | EGFR inhibitor |
|---|
| Indication | non-small cell lung cancer (NSCLC) |
|---|
| Disease area | oncology |
|---|
All known targets
- EGFR
- ALK
- BTK
- CARS1
- CTSC
- ERBB2
- ERBB3
- Egfr
- INSR
- KCNH2
- KDM1A
- NQO2
Mechanisms of action (all sources)
- EGFR INHIBITOR
- Epidermal growth factor receptor erbB1 inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- MLNR
- KDR
- HRH3
- IGF1R
- HDAC6
- JAK3
- TNK2
- HTR1A
- DRD2
- ADORA3
- HTR2A
- SYK
- HTR2B
- CCKAR
- HTR2C
- CHRM2
- NUAK2
- NTRK1
- AAK1
- NR1I2
- NR3C1
- NME2P1
- NME2
- NLK
- NEK9
- NEK7
- NEK3
- NEK2
- NEK1
- OLA1
- OPRM1
- OPA1
- OPRD1
- PKN3
- PKN2
- PKN1
- PKMYT1
- PIP4K2A
- PIM1
- PHKG2
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- CP2D6
- CP3A7
- TP53
- RCOR1
- NTMT1
- NTM1A
- NSD2
- KSYK
- IL3
- IFNG
- IFNB1
- HLAB
- HDAC9
- HDAC8
- HDAC7
- HDAC5
- HDAC4
- HDAC3
- HDAC2
- HDAC11
- HDAC10
- HDAC1
- EML4
- VHL
Drug classes
- Antineoplastic Agents
- Enzyme Inhibitors
- Protein Kinase Inhibitors
- Kinase Inhibitors
- Kinase Inhibitor
- Cytochrome P450 3A4 Inducers
- Breast Cancer Resistance Protein Inhibitors
- Cytochrome P450 3A Inhibitors
- Cytochrome P450 1A2 Inducers
- Tyrosine Kinase Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- TAGRISSO
- Tagrisso
- tagrisso
- AZD9291
- AZD 9291
- osimertinib mesylate
- osimertinib mesilate
- AZD9291 mesylate
- mereletinib
- AZD-9291
- Mereletinib
- AZD-9291 FREE BASE
- Osimertinib [USAN]
- UNII-3C06JJ0Z2O
- 3C06JJ0Z2O
- MereletinibAZD-9291,Osimertinib
- Mereletinib [INN]
- osimertinibum
- OSIMERTINIB [MI]
- OSIMERTINIB [INN]
- Osimertinib (AZD9291)
- Osimertinib; AZD-9291
- mereletinib (obsolete INN)
- OSIMERTINIB [WHO-DD]
- GTPL7719
- CHEMBL3353410
- SCHEMBL14660911
- CHEBI:90943
- AMY9161
- EX-A314
- DTXSID501025961
- HMS3653E10
- HMS3672M05
- BCP08626
- BDBM50029668
- MFCD27988062
- NSC779217
- NSC781254
Reported adverse events
- Blood creatinine increased
- Dry skin
- Erythema multiforme
- Keratitis
- Leukopenia
- Lymphopenia
- Neutropenia
- Pneumonitis
- Pruritus
- Rash
- Stomatitis
- Thrombocytopenia
Look up OSIMERTINIB in the interactive SynDRA portal →